Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PURR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's report on Hyperliquid Strategies' July 2, 2025 balance sheet includes a going-concern warning due to significant working capital deficiency, significant losses, and the need to raise additional funds.
- Material Weakness (new) — The filing discloses the risk of material weaknesses in internal control over financial reporting, which could undermine investor confidence and lead to regulatory sanctions.
- Concentration (new) — The company's principal asset is HYPE tokens, with approximately $580 million held at the time of the business combination, and substantially all HYPE is held with a single custodian, Anchorage, creating a single point of failure.
- Related-party (new) — The company's advisor, Chardan, received substantial equity compensation including 7,761,860 shares and 27,394,800 warrants, and also serves as the counterparty to the committed equity facility, creating potential conflicts of interest.
- Dilution (new) — The committed equity facility allows the company to issue up to 160 million shares, a 67% increase over current shares outstanding, and the advisor warrants have exercise prices of $9.375, $12.50, and $18.75 per share, potentially diluting existing shareholders.
- Cryptocurrency Treasury Strategy (new) — Filing discloses a named Bitcoin treasury/financing strategy (1940-Act risk). On minimal cash with going-concern doubt, this non-standard treasury pivot is material.
Hyperliquid Strategies files S-1 for up to $2.5B committed equity facility with Chardan; company may issue 160M shares
Filed September 15, 2026 · ~2 min read
Key Changes
-
high
As discussed in Note 1, on Decemb…
Notes: Subsequent Events verify on EDGAR → -
high
The company may issue up to 160,000,000 shares to Chardan under a purchase agreement, increasing shares outstanding from 237,919,288 to 397,919,288.
The Offering verify on EDGAR → -
high
The company has a committed equity facility allowing it to sell up to $2.5 billion of common stock to Chardan at its discretion until December 2, 2028.
Prospectus Summary verify on EDGAR → -
high
The company held approximately $580 million in HYPE tokens and $310 million in cash at the time of the business combination, with HYPE token price ranging from $10.26 to $87.94.
Prospectus Summary verify on EDGAR → -
high
The company reported a GAAP net loss of $0.6 million for the period from June 13, 2025 (inception) through June 30, 2025, despite a net income of $305.5 million for fiscal 2026 driven by unrealized gains on HYPE tokens.
-
high
The company's auditor issued a going-concern warning for Hyperliquid Strategies, citing significant working capital deficiency, significant losses, and the need to raise additional funds.
Experts view on EDGAR → -
medium
The company intends to use net proceeds from the facility for general corporate purposes, including potential purchases of HYPE tokens.
Use of Proceeds verify on EDGAR →
Summary
Hyperliquid Strategies Inc. has filed an S-1 registration statement for a committed equity facility with Chardan, under which the company may issue up to 160 million shares of common stock, increasing shares outstanding from 237.9 million to 397.9 million.
The facility allows the company to sell up to $2.5 billion of stock to Chardan at its discretion until December 2028, with approximately $1.4 billion remaining as of September 8, 2026. The company's primary assets are HYPE tokens and cash, with approximately $580 million in HYPE tokens and $310 million in cash at the time of the business combination.
The company reported a GAAP net loss of $0.6 million for the period from inception through June 30, 2025, despite a net income of $305.5 million for fiscal 2026 driven by unrealized gains on HYPE tokens. Several red flags are present. The auditor's report includes a going-concern warning for Hyperliquid Strategies, citing significant working capital deficiency, significant losses, and the need to raise additional funds. The filing also discloses the risk of material weaknesses in internal control over financial reporting. The company's concentration in HYPE tokens, held with a single custodian, Anchorage, creates a single point of failure. Additionally, the advisor, Chardan, received substantial equity compensation and serves as the counterparty to the equity facility, creating potential conflicts of interest. The facility and advisor warrants also present significant dilution risk to existing shareholders. Investors should carefully review the full prospectus, including the audited financial statements and risk factors, before making any investment decision. The company's reliance on a volatile digital asset, going-concern doubts, and potential dilution from the equity facility are key considerations.
Section-by-Section Diff
The Offering · The Offering
Hyperliquid Strategies Inc may issue up to 160,000,000 shares to Chardan under a purchase agreement, increasing shares outstanding from 237,919,288 to 397,919,288.
Added in current filing · verify on EDGAR →
Up to 160,000,000 shares of Common Stock that we may elect, in our sole discretion, to issue and sell to Chardan, from time to time under the Purchase Agreement.
The company may issue up to 160 million shares to Chardan under a purchase agreement, at its discretion. This is a primary offering, meaning proceeds go to the company, not to selling stockholders.
Added in current filing · verify on EDGAR →
237,919,288 shares as of September 8, 2026.
The company had 237,919,288 shares of common stock outstanding before the offering. This is the baseline for calculating dilution.
Added in current filing · verify on EDGAR →
397,919,288 shares, assuming the sale of 160,000,000 shares of our Common Stock under the Purchase Agreement.
If all 160 million shares are issued, total shares outstanding would rise to 397,919,288, a 67% increase. This significant dilution affects existing shareholders' ownership percentage.
Prospectus Summary · Prospectus Summary
Hyperliquid Strategies Inc is a holding company formed via a business combination, holding HYPE tokens and cash, with a committed equity facility to sell up to $2.5 billion of common stock.
Added in current filing · verify on EDGAR →
we have the right from time to time at our option to direct Chardan to purchase up to $2.5 billion of shares of our Common Stock
The company has a committed equity facility with Chardan allowing it to sell up to $2.5 billion of common stock at its discretion. This is a significant potential source of dilution for existing shareholders, as the company can issue shares over time without further stockholder approval, subject to the Exchange Cap.
Added in current filing · verify on EDGAR →
the Company held approximately $580 million in HYPE Tokens (based on an agreed spot price of HYPE of $46.372, as used in the Transaction Agreement) and had cash of approximately $310 million on its balance sheet (prior to payment of expenses related to the Transactions)
The company's principal assets are HYPE tokens and cash. The HYPE token value is based on an agreed spot price at the time of the transaction, not a current market price, and the token is highly volatile. This concentration in a single digital asset is a key risk factor for investors.
Added in current filing · verify on EDGAR →
the Company issued 7,761,860 Advisor Issued Shares and 27,394,800 Advisor Warrants to the Advisor
The advisor received a substantial equity stake: 7,761,860 shares (5% of outstanding) and warrants to purchase 27,394,800 shares (15% of fully diluted). The warrants have exercise prices of $9.375, $12.50, and $18.75 per share. This compensation is significant and dilutive to other shareholders.
Added in current filing · verify on EDGAR →
we transferred $1.325 million in cash, various developmental assets and patents related to Sonnet’s tumor delivery platforms, certain employees and Sonnet’s Australian subsidiary to Guidant, and provided a deferred purchase price of $1.0 million subsequent to the execution of the APA. In exchange, we received a 40% common stock interest in Guidant.
The company disposed of Sonnet's legacy assets to Guidant in exchange for a 40% equity interest. This transaction removed the biotech assets from the company's direct ownership, leaving the company primarily as a holder of HYPE tokens and cash. The value of the Guidant interest is uncertain.
Added in current filing · verify on EDGAR →
There can be no assurances that any holders of CVRs will receive any CVR Shares with respect thereto.
Holders of contingent value rights (CVRs) may receive nothing if the Sonnet legacy assets are not monetized within three years or if deductions exceed proceeds. This creates uncertainty for former Sonnet stockholders and reflects the company's discretion over the legacy assets.
Use of Proceeds · Use of Proceeds
Company will not receive proceeds from Chardan's sales; may receive up to $2.5B gross from Chardan under Purchase Agreement, with ~$1.4B remaining as of Sep 8, 2026.
Added in current filing · verify on EDGAR →
We may receive up to $2.5 billion in aggregate gross proceeds from Chardan under the Purchase Agreement in connection with sales of our shares of our Common Stock to Chardan pursuant to the Purchase Agreement from time to time.
The company may receive up to $2.5 billion in gross proceeds from Chardan under the Purchase Agreement. This is a potential amount, not guaranteed, and actual proceeds may be less.
Added in current filing · verify on EDGAR →
As of September 8, 2026, we had received approximately $1.1 billion in aggregate gross proceeds, leaving approximately $1.4 billion in potential gross proceeds we may receive after that date.
The company has already received about $1.1 billion of the potential $2.5 billion, leaving about $1.4 billion that could still be received. This shows the current state of the facility.
Added in current filing · verify on EDGAR →
We intend to use any net proceeds from any sales of shares of our Common Stock to Chardan under the Facility for general corporate purposes, including potential purchases of HYPE Tokens.
The company plans to use net proceeds for general corporate purposes, including buying HYPE Tokens. This indicates a significant portion of proceeds may be used to acquire the digital asset central to its strategy.
Added in current filing · verify on EDGAR →
All of the shares of our Common Stock offered by Chardan will be solely for Chardan’s account. We will not receive any of the proceeds from these sales.
The shares being sold by Chardan are for Chardan's own account, so the company receives no proceeds from those sales. This clarifies that the offering is secondary, not primary.
Risk Factors · Risk Factors
Risks center on the Chardan equity facility, HYPE token volatility, regulatory uncertainty, and custody concentration with Anchorage.
Added in current filing · verify on EDGAR →
Under the Purchase Agreement with Chardan, we may sell to Chardan up to $2.5 billion of shares of our Common Stock (the “Total Commitment”)
The company has a committed equity facility allowing it to sell up to $2.5 billion of common stock to Chardan at its discretion until December 2, 2028. This creates potential for significant dilution and downward pressure on the stock price, as sales are at market prices and Chardan may resell shares immediately.
Added in current filing · verify on EDGAR →
Since December 4, 2024 (the first date for which public information of the HYPE Token price is available at TradingView.com) through September 8, 2026, the token price of HYPE, based on the price reported by TradingView.com as of 23:59 p.m. UTC on each day, has ranged from as low as $10.26 (April 6, 2025) to as high as $87.94 (September 6, 2026).
The company's financial results and stock price are directly tied to the price of HYPE, which has been extremely volatile, ranging from $10.26 to $87.94 in under two years. A decline in HYPE could proportionately reduce the value of the company's common stock.
Added in current filing · verify on EDGAR →
Our HYPE is currently held by Anchorage Digital Bank National Association (“Anchorage”), which is a qualified custodian as defined under the Investment Advisers Act of 1940.
Substantially all of the company's HYPE tokens are held with a single custodian, Anchorage. This concentration creates a single point of failure; if Anchorage experiences operational, security, or regulatory issues, the company's ability to access its HYPE could be impaired.
Added in current filing · verify on EDGAR →
Neither the SEC nor any other U.S. federal or state regulator has publicly stated whether they believe that HYPE is a “security,” nor has any court addressed the status of HYPE under the U.S. federal securities laws or similar laws.
The company acknowledges that HYPE could be classified as a security by regulators or courts, which would subject it to additional regulation and could require registration as an investment company. This uncertainty could materially impact the company's operations and the value of its securities.
Added in current filing · verify on EDGAR →
If we were deemed to be an investment company under the Investment Company Act, applicable restrictions likely would make it impractical for us to continue segments of our business as currently contemplated.
The company's substantial HYPE holdings could cause it to be deemed an investment company under the Investment Company Act if HYPE is classified as a security. Such a determination would impose severe restrictions on its operations and could force it to change its business model.
Added in current filing · verify on EDGAR →
In addition, in certain cases our digital asset trading service providers may be affiliated with our custodians, which may give rise to conflicts of interest. For example, Anchorage also acts as one of the execution agents for our HYPE accumulation. Because the same provider both holds our digital assets in custody and executes our HYPE accumulation transactions, it may have less incentive to obtain best execution, the quality and pricing of our transactions may be less transparent, and the prices at which we acquire HYPE may be less favorable than they would be if custody and execution were performed by unaffiliated parties.
The company discloses that Anchorage serves as both custodian and execution agent for HYPE accumulation, creating a conflict of interest that could lead to worse pricing and less transparency. This is a company-specific risk tied to a named counterparty.
Added in current filing · verify on EDGAR →
Commencing in November 2025, approximately 238 million HYPE Tokens (representing 23.8% of the total current supply) allocated to core contributors began vesting on a monthly basis following a one-year lockup period after the Token Generation Event on November 29, 2024.
A large tranche of HYPE tokens (23.8% of supply) began vesting in November 2025, which could create significant selling pressure and depress the value of the company's treasury holdings. The company does not know the exact vesting schedule, adding uncertainty.
Added in current filing · verify on EDGAR →
Commencing in November 2025, approximately 238 million HYPE Tokens allocated to the Hyperliquid Foundation and core contributors began vesting. As these tokens vest and are staked, the Foundation and core contributors may collectively control or significantly influence a majority of validator voting weight, and therefore have the ability to determine the outcome of protocol governance decisions.
The company's primary treasury asset, HYPE, is governed by a protocol where insiders may gain majority voting control as tokens vest. This concentration could lead to protocol changes that benefit insiders at the expense of other HYPE holders, including the company.
MD&A · Management's Discussion and Analysis
Hyperliquid Strategies Inc is a digital asset treasury company that accumulates and stakes HYPE tokens, reporting $305.5M net income for FY2026.
Added in current filing · verify on EDGAR →
Our net income (loss) was $305.5 million and ($0.6) million for the year ended June 30, 2026 and for the period from June 13, 2025 (inception) through June 30, 2025, respectively.
The company reports a net income of $305.5 million for fiscal 2026, a significant swing from the prior period's net loss of $0.6 million. This is driven largely by unrealized gains on HYPE tokens and a deferred tax liability, not necessarily operating profitability.
Added in current filing · verify on EDGAR →
Unrealized gain on HYPE digital tokens for the year ended June 30, 2026 was $709.9 million, resulting from the fair value changes of HYPE at June 30, 2026.
The company recognized a $709.9 million unrealized gain from the increase in fair value of its HYPE token holdings. This is a non-cash item that significantly inflates net income and is subject to volatility.
Added in current filing · verify on EDGAR →
We recognized an income tax expense of $183.5 million for the year ended June 30, 2026 related to the creation of a deferred tax liability at the closing of the transaction in addition to a deferred tax liability created by the increase in value of our HYPE digital tokens during the period.
A large deferred tax expense of $183.5 million was recorded, primarily due to the unrealized gains on HYPE tokens. This is a non-cash charge that reduces net income but does not affect current cash flows.
Added in current filing · verify on EDGAR →
As of June 30, 2026, we had cash and cash equivalents of $137.9 million and HYPE digital assets with a fair value of $1.9 billion, working capital (inclusive of cash and cash equivalents) of $148.7 million and stockholders’ equity of $1.9 billion.
The company holds $1.9 billion in HYPE tokens, which represents the vast majority of its assets. This concentration in a single digital asset exposes the company to significant price volatility.
Added in current filing · verify on EDGAR →
As of June 30, 2026, 76,063,600 shares of common stock have been issued under the Equity Facility for gross proceeds of $646.6 million. Subsequent to June 30, 2026, as of September 8, 2026, 36,888,500 shares of common stock have been issued under the Equity Facility for gross proceeds of $424.9 million.
The company has aggressively utilized its equity facility with Chardan, raising over $1 billion in gross proceeds through share issuances. This dilutes existing shareholders and indicates ongoing capital needs.
Business · Business
Biotech company with going concern doubt, recent business combination, and collaboration revenue from Alkem and New Life agreements.
Added in current filing · verify on EDGAR →
On July 11, 2025, the Company entered into a definitive Business Combination Agreement (as amended on September 22, 2025, the “BCA”) with Rorschach I LLC (“Rorschach”), Hyperliquid Strategies Inc. (“HSI”), TBS Merger Sub Inc., and Rorschach Merger Sub, LLC, pursuant to which, subject to the terms and conditions contained in the BCA, Rorschach Merger Sub, LLC, will merge with and into Rorschach with Rorschach surviving as a direct wholly owned subsidiary of HSI and TBS Merger Sub Inc. will merge with and into Sonnet, with Sonnet surviving as a direct wholly owned subsidiary of HSI.
The company completed a business combination on December 2, 2025, becoming a wholly owned subsidiary of HSI. Legacy stockholders receive contingent value rights tied to future biotech asset value. This restructuring changes the company's ownership and control structure.
Added in current filing · verify on EDGAR →
The Company believes its cash and cash equivalents at September 30, 2025 of $5.1 million will fund the Company’s projected operations into February 2026. Substantial additional financing will be needed by the Company to fund its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
The company has only $5.1 million in cash, enough to fund operations only into February 2026, and explicitly states substantial doubt about its ability to continue as a going concern. This is a critical risk for investors.
Added in current filing · verify on EDGAR →
Concurrently with the signing of the BCA, the Company raised an aggregate of $5.5 million in a private placement to accredited investors through the issuance and sale of an aggregate of 5,500 shares of non-voting Series 5 convertible preferred stock, convertible into up to an aggregate of 4,400,000 shares of common stock, and five-year warrants to purchase up to an aggregate of 8,800,000 shares of common stock at an exercise price of $1.25 per share.
The company raised $5.5 million through a private placement of non-voting convertible preferred stock and warrants. The preferred stock carries a 6% cumulative dividend and a liquidation preference, and the warrants have significant potential dilution.
Added in current filing · verify on EDGAR →
Under the terms of the Alkem Agreement, Alkem paid the Company $1.0 million in upfront payments and will pay up to an additional $1.0 million in milestone payments. Additionally, the Company is entitled to receive a royalty equal to a percentage in the low double digits of the net sales of the Product upon commercialization of SON-080 in India, less certain expenses as set forth in the Alkem Agreement.
The company entered into a licensing agreement with Alkem for SON-080 in India, receiving $1.0 million upfront with potential for additional milestones and royalties. This provides near-term revenue but is limited to a single territory and product.
Added in current filing · verify on EDGAR →
New Life paid the Company an aggregate of $1.0 million in non-refundable upfront cash payments in connection with the execution of the New Life Agreement. The related collaboration revenue was fully recognized by December 31, 2023, as the Company had completed its performance obligations under the New Life Agreement. In December 2024, New Life informed the Company that it has elected to move its business in a different direction and provided the Company with written notice of its intention to exercise its Give Back Option, which is the right to give back the rights with respect to Products in the DPN Field in one or more countries in the Exclusive Territory.
The company previously recognized $1.0 million from New Life for rights in Southeast Asia, but New Life has indicated it will give back those rights. This reduces future revenue potential from that territory.
Added in current filing · verify on EDGAR →
In accordance with the BCA, any cash proceeds in excess of $3.0 million received from the exercise of warrants may not be spent by the Company without the prior written consent of Rorschach.
The company's ability to spend warrant proceeds above $3.0 million is restricted by Rorschach, limiting financial flexibility post-merger.
Added in current filing · verify on EDGAR →
Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to $25.0 million in aggregate gross purchase price of newly issued shares of the Company’s common stock, of which $24.7 million is available to be sold as of September 30, 2025.
The company has a committed equity facility with Chardan allowing it to sell up to $25.0 million of newly issued shares, with $24.7 million still available as of September 30, 2025. This provides a source of future primary capital at the company's discretion, but sales would dilute existing shareholders.
Added in current filing · verify on EDGAR →
On November 7, 2024, the Company closed a public offering of common stock and certain warrants through Chardan, as underwriter, for net proceeds of $4.2 million through the issuance and sale of 155,000 shares of its common stock, pre-funded warrants to purchase up to 956,111 shares of common stock, and accompanying common warrants to purchase up to an aggregate of 2,222,222 shares of its common stock.
The company raised $4.2 million in net proceeds from a public offering in November 2024, issuing common stock and warrants. This reflects recent capital-raising activity and potential dilution from warrant exercises.
Selling Stockholders · Selling Stockholders
Chardan may resell up to 160M shares issuable under a committed equity facility; it currently holds 383,278 shares (1.6%).
Added in current filing · verify on EDGAR →
up to 160,000,000 shares of our Common Stock that have been or may be issued by us to Chardan pursuant to the Purchase Agreement
The prospectus registers up to 160 million shares for resale by Chardan under the committed equity facility. These shares are issued at the company's discretion and are not currently outstanding, so the actual number sold may be lower or higher.
Added in current filing · view on EDGAR → · paraphrased
383,278 | 1.6% | 160,000,000 | 383,278 | 1.6%
Chardan currently holds 383,278 shares (1.6% of 237,919,288 outstanding). The table assumes all 160 million shares are sold, leaving Chardan with the same 383,278 shares and 1.6% ownership, because the newly issued shares are excluded from beneficial ownership until actually issued.
Added in current filing · verify on EDGAR →
the Purchase Agreement prohibits us from issuing and selling any shares of Common Stock to Chardan to the extent such shares of Common Stock, when aggregated with all other shares of our Common Stock then beneficially owned by Chardan, would cause Chardan’s beneficial ownership of our Common Stock to exceed 4.99%.
The Purchase Agreement caps Chardan's beneficial ownership at 4.99%, limiting dilution from the facility at any single point in time. This is a standard protective provision for committed equity facilities.
Added in current filing · verify on EDGAR →
Chardan elected to receive its fee in shares, and as such, the number of shares issued to Chardan was $4.0 million, divided by $6.25 per share, for approximately 0.64 million shares of the Company Common Stock.
Chardan received approximately 0.64 million shares as its merger advisory fee for the Business Combination, valued at $4.0 million at $6.25 per share. This is part of Chardan's existing 383,278 share position, indicating prior compensation in equity.
Added in current filing · verify on EDGAR →
Chardan elected to receive its fee in shares, and as such, the number of shares issued to Chardan was $9.6 million, divided by $6.25 per share, for approximately 1.54 million shares of the Company Common Stock.
Chardan received approximately 1.54 million shares as its fee for advising on the Closing PIPE, valued at $9.6 million at $6.25 per share. Combined with the merger fee, Chardan's total share-based compensation from these transactions is about 2.18 million shares.
Experts · Experts
Auditors issued going-concern warnings for Hyperliquid Strategies, Rorschach I LLC, and Sonnet BioTherapeutics Holdings.
Added in current filing · verify on EDGAR →
The audit report covering the July 2, 2025 consolidated financial statements contains an explanatory paragraph that states that Hyperliquid Strategies, Inc. has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations that, raise substantial doubt about its ability to continue as a going concern.
The auditor's report on Hyperliquid Strategies' July 2, 2025 balance sheet includes a going-concern warning due to significant working capital deficiency, significant losses, and the need to raise additional funds. This indicates the company may not be able to continue operations without new financing.
Added in current filing · verify on EDGAR →
The audit report covering the June 30, 2025 consolidated financial statements contains an explanatory paragraph that states that Rorschach I LLC has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations, that raise substantial doubt about its ability to continue as a going concern.
The auditor's report on Rorschach I LLC's June 30, 2025 financial statements includes a going-concern warning due to significant working capital deficiency, significant losses, and the need to raise additional funds. This indicates the entity may not be able to continue operations without new financing.
Added in current filing · verify on EDGAR →
The audit report covering the September 30, 2025 consolidated financial statements contains an explanatory paragraph that states that Sonnet BioTherapeutics Holdings, Inc. has incurred recurring losses and negative cash flows from operations since inception and will require substantial additional financing to continue to fund its research and development activities that raise substantial doubt about its ability to continue as a going concern.
The auditor's report on Sonnet BioTherapeutics Holdings' September 30, 2025 financial statements includes a going-concern warning due to recurring losses, negative cash flows, and the need for substantial additional financing. This indicates the company may not be able to continue operations without new financing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 15, 2026 · How we verify